Advertisement

Science China Life Sciences

, Volume 59, Issue 12, pp 1270–1281 | Cite as

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD

  • Yaping Yan
  • Yujing Li
  • Ying Fu
  • Li Yang
  • Lei Su
  • Kaibin Shi
  • Minshu Li
  • Qiang Liu
  • Aimee Borazanci
  • Yaou Liu
  • Yong He
  • Jeffrey L. Bennett
  • Timothy L. Vollmer
  • Fu-Dong Shi
Open Access
Research Paper

Abstract

We characterized a unique group of patients with neuromyelitis optica spectrum disorder (NMOSD) who carried autoantibodies of aquaporin-4 (AQP4) and myelin-oligodendrocyte glycoprotein (MOG). Among the 125 NMOSD patients, 10 (8.0%) were AQP4- and MOG-ab double positive, and 14 (11.2%) were MOG-ab single positive. The double-positive patients had a multiphase disease course with a high annual relapse rate (P=0.0431), and severe residual disability (P>0.0001). Of the double- positive patients, 70% had MS-like brain lesions, more severe edematous, multifocal regions on spinal magnetic resonance imaging (MRI), pronounced decreases of retinal nerve fiber layer thickness and atrophy of optic nerves. In contrast, patients with only MOG-ab had a higher ratio of monophasic disease course and mild residual disability. Spinal cord MRI illustrated multifocal cord lesions with mild edema, and brain MRIs showed more lesions around lateral ventricles. NMOSD patients carrying both autoantibodies to AQP4 and MOG existed and exhibited combined features of prototypic NMO and relapsing- remitting form of MS, whereas NMOSD with antibodies to MOG only exhibited an “intermediate” phenotype between NMOSD and MS. Our study suggests that antibodies against MOG might be pathogenic in NMOSD patients and that determination of anti-MOG antibodies maybe instructive for management of NMOSD patients.

Keywords

MOG antibody AQP4 antibody neuromyelitis optica spectrum disorder phenotype 

Notes

Acknowledgements

We thank Neuroimmunology teams in Tianjin and Barrow for support. This study was supported by National Basic Research Program of China Grant (2013CB96690), the Natural Science Foundation of China Grants (81100888, 81230028, 81371372), the National Key Clinical Specialty Construction Program of China, US National Institute of Health (R01AI083294), and the American Heart Association (14GRNT-18970031).

References

  1. Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., and Reindl, M. (2003). Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349, 139–145.CrossRefPubMedGoogle Scholar
  2. Bettelli, E., Baeten, D., Jager, A., Sobel, R.A., and Kuchroo, V.K. (2006). Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116, 2393–2402.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Dale, R.C., de Sousa, C., Chong, W.K., Cox, T.C., Harding, B., and Neville, B.G. (2000). Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123 Pt 12, 2407–2422.Google Scholar
  4. Eichel, R., Meiner, Z., Abramsky, O., and Gotkine, M. (2008). Acute disseminating encephalomyelitis in neuromyelitis optica: closing the floodgates. Arch Neurol 65, 267–271.CrossRefPubMedGoogle Scholar
  5. Granieri, L., Marnetto, F., Valentino, P., Frau, J., Patanella, A.K., Nytrova, P., Sola, P., Capobianco, M., Jarius, S., and Bertolotto, A. (2012). Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS One 7, e38896.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Jarius, S., Ruprecht, K., Wildemann, B., Kuempfel, T., Ringelstein, M., Geis, C., Kleiter, I., Kleinschnitz, C., Berthele, A., Brettschneider, J., Hellwig, K., Hemmer, B., Linker, R.A., Lauda, F., Mayer, C.A., Tumani, H., Melms, A., Trebst, C., Stangel, M., Marziniak, M., Hoffmann, F., Schippling, S., Faiss, J.H., Neuhaus, O., Ettrich, B., Zentner, C., Guthke, K., Hofstadt-van Oy, U., Reuss, R., Pellkofer, H., Ziemann, U., Kern, P., Wandinger, K.P., Bergh, F.T., Boettcher, T., Langel, S., Liebetrau, M., Rommer, P.S., Niehaus, S., Munch, C., Winkelmann, A., Zettl, U.U., Metz, I., Veauthier, C., Sieb, J.P., Wilke, C., Hartung, H.P., Aktas, O., and Paul, F. (2012). Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9, 14.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Jiao, Y., Fryer, J.P., Lennon, V.A., McKeon, A., Jenkins, S.M., Smith, C.Y., Quek, A.M., Weinshenker, B.G., Wingerchuk, D.M., Shuster, E.A., Lucchinetti, C.F., and Pittock, S.J. (2014). Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol 71, 48–54.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Kezuka, T., Usui, Y., Yamakawa, N., Matsunaga, Y., Matsuda, R., Masuda, M., Utsumi, H., Tanaka, K., and Goto, H. (2012). Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol 32, 107–110.CrossRefPubMedGoogle Scholar
  9. Kitley, J., Leite, M.I., Kuker, W., Quaghebeur, G., George, J., Waters, P., Woodhall, M., Vincent, A., and Palace, J. (2013). Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 70, 1375–1381.CrossRefPubMedGoogle Scholar
  10. Kitley, J., Waters, P., Woodhall, M., Leite, M.I., Murchison, A., George, J., Kuker, W., Chandratre, S., Vincent, A., and Palace, J. (2014). Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71, 276–283.CrossRefPubMedGoogle Scholar
  11. Kitley, J., Woodhall, M., Waters, P., Leite, M.I., Devenney, E., Craig, J., Palace, J., and Vincent, A. (2012). Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79, 1273–1277.CrossRefPubMedGoogle Scholar
  12. Kuhle, J., Pohl, C., Mehling, M., Edan, G., Freedman, M.S., Hartung, H.P., Polman, C.H., Miller, D.H., Montalban, X., Barkhof, F., Bauer, L., Dahms, S., Lindberg, R., Kappos, L., and Sandbrink, R. (2007). Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 356, 371–378.CrossRefPubMedGoogle Scholar
  13. Lennon, V.A., Kryzer, T.J., Pittock, S.J., Verkman, A.S., and Hinson, S.R. (2005). IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202, 473–477.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Liu, J., Yeung, P.K., Cheng, L., Lo, A.C., Chung, S.S., and Chung, S.K. (2015). Epac2-deficiency leads to more severe retinal swelling, glial reactivity and oxidative stress in transient middle cerebral artery occlusion induced ischemic retinopathy. Sci China Life Sci 58, 521–530.CrossRefPubMedGoogle Scholar
  15. Mader, S., Gredler, V., Schanda, K., Rostasy, K., Dujmovic, I., Pfaller, K., Lutterotti, A., Jarius, S., Di Pauli, F., Kuenz, B., Ehling, R., Hegen, H., Deisenhammer, F., Aboul-Enein, F., Storch, M.K., Koson, P., Drulovic, J., Kristoferitsch, W., Berger, T., and Reindl, M. (2011). Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8, 184.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Marta, C.B., Oliver, A.R., Sweet, R.A., Pfeiffer, S.E., and Ruddle, N.H. (2005). Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci USA 102, 13992–13997.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Matthews, L., Marasco, R., Jenkinson, M., Kuker, W., Luppe, S., Leite, M.I., Giorgio, A., De Stefano, N., Robertson, N., Johansen-Berg, H., Evangelou, N., and Palace, J. (2013). Distinction of seropositive NMO spectrum disorder and MSbrain lesion distribution. Neurology 80, 1330–1337.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Papadopoulos, M.C., and Verkman, A.S. (2012). Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11, 535–544.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Pittock, S.J., Lennon, V.A., Krecke, K., Wingerchuk, D.M., Lucchinetti, C.F., and Weinshenker, B.G. (2006). Brain abnormalities in neuromyelitis optica. Arch Neurol 63, 390–396.CrossRefPubMedGoogle Scholar
  20. Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F.D., Montalban, X., O’ Connor, P., Sandberg-Wollheim, M., Thompson, A.J., Waubant, E., Weinshenker, B., and Wolinsky, J.S. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69, 292–302.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Probstel, A.K., Rudolf, G., Dornmair, K., Collongues, N., Chanson, J.B., Sanderson, N.S., Lindberg, R.L., Kappos, L., de Seze, J., and Derfuss, T. (2015). Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 12, 46.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Ratelade, J., Zhang, H., Saadoun, S., Bennett, J.L., Papadopoulos, M.C., and Verkman, A.S. (2012). Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 123, 861–872.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Reindl, M., Di Pauli, F., Rostasy, K., and Berger, T. (2013). The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9, 455–461.CrossRefPubMedGoogle Scholar
  24. Rostasy, K., Mader, S., Hennes, E.M., Schanda, K., Gredler, V., Guenther, A., Blaschek, A., Korenke, C., Pritsch, M., Pohl, D., Maier, O., Kuchukhidze, G., Brunner-Krainz, M., Berger, T., and Reindl, M. (2013). Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 19, 1052–1059.CrossRefPubMedGoogle Scholar
  25. Saadoun, S., Waters, P., Bell, B.A., Vincent, A., Verkman, A.S., and Papadopoulos, M.C. (2010). Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133, 349–361.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Saadoun, S., Waters, P., Owens, G.P., Bennett, J.L., Vincent, A., and Papadopoulos, M.C. (2014). Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2, 35.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Sato, D.K., Callegaro, D., Lana-Peixoto, M.A., Waters, P.J., de Haidar Jorge, F.M., Takahashi, T., Nakashima, I., Apostolos-Pereira, S.L., Talim, N., Simm, R.F., Lino, A.M., Misu, T., Leite, M.I., Aoki, M., and Fujihara, K. (2014). Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82, 474–481.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Tackley, G., Kuker, W., and Palace, J. (2014). Magnetic resonance imaging in neuromyelitis optica. Mult Scler, 20, 1153–1164.CrossRefPubMedGoogle Scholar
  29. Tanaka, M., and Tanaka, K. (2014). Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 270, 98–99.CrossRefPubMedGoogle Scholar
  30. Waters, P.J., McKeon, A., Leite, M.I., Rajasekharan, S., Lennon, V.A., Villalobos, A., Palace, J., Mandrekar, J.N., Vincent, A., Bar-Or, A., and Pittock, S.J. (2012). Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78, 665–671; 669.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Weinshenker, B.G., and Wingerchuk, D.M. (2014). The two faces of neuromyelitis optica. Neurology 82, 466–467.CrossRefPubMedGoogle Scholar
  32. Wingerchuk, D.M., Lennon, V.A., Lucchinetti, C.F., Pittock, S.J., and Weinshenker, B.G. (2007). The spectrum of neuromyelitis optica. Lancet Neurol 6, 805–815.CrossRefPubMedGoogle Scholar
  33. Woodhall, M., Coban, A., Waters, P., Ekizoglu, E., Kurtuncu, M., Shugaiv, E., Turkoglu, R., Akman-Demir, G., Eraksoy, M., Vincent, A., and Tuzun, E. (2013). Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. J Neurol Sci 335, 221–223.CrossRefPubMedGoogle Scholar
  34. Zhou, D., Srivastava, R., Nessler, S., Grummel, V., Sommer, N., Bruck, W., Hartung, H.P., Stadelmann, C., and Hemmer, B. (2006). Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 103, 19057–19062.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2016

Authors and Affiliations

  • Yaping Yan
    • 1
  • Yujing Li
    • 1
  • Ying Fu
    • 1
  • Li Yang
    • 1
  • Lei Su
    • 1
  • Kaibin Shi
    • 1
  • Minshu Li
    • 1
  • Qiang Liu
    • 1
    • 2
  • Aimee Borazanci
    • 2
  • Yaou Liu
    • 1
  • Yong He
    • 3
  • Jeffrey L. Bennett
    • 4
  • Timothy L. Vollmer
    • 4
  • Fu-Dong Shi
    • 1
    • 2
  1. 1.Departments of Neurology and Immunology, Tianjin Neurological InstituteTianjin Medical University General HospitalTianjinChina
  2. 2.Department of Neurology, Barrow Neurological InstituteSt. Joseph’s Hospital and Medical CenterPhoenixUSA
  3. 3.State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain ResearchBeijing Normal UniversityBeijingChina
  4. 4.Department of NeurologyUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations